Melanoma and other skin tumours - 1037O - MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)
Área Reservada
Subscrever Newsletter